

EU HTA R – Early Insights and Ideas for the 2027/28 Revision – JCA SG Perspective

Anne Willemsen

Chair, JCA Subgroup & Senior Advisor, ZIN
awillemsen@zinl.nl



First experiences of the Joint Clinical Assessments

In March 2025, the first Joint Clinical Assessments (JCA) of a medicinal products started. One year later, we have 13 JCA on medicinal products ongoing and in total there are 16 different HTA organisations acting as assessor or co-assessor for these JCAs. The majority of these JCAs have now finalized the assessment scoping phase and are either awaiting a submission dossier from the Health Technology Developer (HTD) or are in the confirmation check of the dossier. Although there are no JCAs publicly available yet, can we already explore

procedural learnings of these first JCAs? We will explore the first experiences on the parallel running of JCAs and the ongoing EMA Marketing Authorization Applications as well as early insights into general dossier expectations. These early insights not only relevant to support the upcoming JCAs, but are also particularly relevant given the upcoming evaluation of the HTA Regulation, and the Member States report on the added value of the joint work.